Fluorogenic substrate assay of antithrombin III: a clinical study.
The fluorogenic substrate assay of antithrombin III (AT III) was compared with a thrombin inhibition (two-stage) clotting test and a radial immunodiffusion assay. Normal ranges based on a population of 25 individuals were 88-121% (fluorogenic substrate), 72-111% (clotting) and 22.5-35.3 mg/dl (RID). A clinical comparison of the methods showed a linear relationship between the fluorogenic substrate and immunologic methods (r = 0.69, p less than 0.005), as well as between the fluorogenic substrate and clotting methods (r = 0.75, p less than 0.005). The fluorogenic substrate assay reflected the highest incidence of low AT III levels in all three clinical groups included (36 patients with arteriosclerosis, 18 with fractures and 37 with thrombosis/embolism).
D000990:Antithrombin III / Q000032:analysis*; D001161:Arteriosclerosis / Q000097:blood*; D005456:Fluorescent Dyes; D006801:Humans; D005779:Immunodiffusion; D010649:Phenylalanine / Q000031:analogs & derivatives; D012784:Shoulder Fractures / Q000097:blood; D013379:Substrate Specificity; D013923:Thromboembolism / Q000097:blood*
D005456:Fluorescent Dyes; D010649:Phenylalanine; D000990:Antithrombin III